Microba Life Sciences Ltd

Microba Investor Hub - Webinars

Microba Investor Hub

Microba Investor Hub - Corporate Governance

Microba Investor Hub - Shareholder Information

Corporate

Microba Investor Hub - News & Media

Microba Investor Hub - Announcements

DM Sans

Analyst Report - Morgans - Initiating coverage.pdf

Microba Life Sciences (MAP) is an emerging leader in the microbiome industry specialising in gut health testing and therapeutic development.

The company provides a comprehensive end-to-end solution, encompassing internally developed tests and therapeutic candidates generated via its discovery engine and artificial intelligence (AI) capabilities.

In collaboration with renowned microbiome specialists worldwide, MAP stands out as a distinctive value proposition, offering high-margin products and opportunities through its therapeutics discovery platform.

The expanding testing services business and increasing awareness among healthcare professionals about the pivotal role of the microbiome are driving a surge in demand. This heightened awareness is fueling increased interest in microbiome-related services, products, and advancements, indicating a growing recognition of its impact on overall health across diverse medical applications.

We initiate coverage of MAP with a valuation and target price of A$0.35 p/s with a Speculative Buy recommendation.